These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7907334)

  • 1. Recovery of antitumor CD4+ T cell responsiveness, suppressed in the tumor-bearing state, by release from tumor burden.
    Zou JP; Nagata T; Yamamoto N; Ono S; Fujiwara H; Hamaoka T
    J Cancer Res Clin Oncol; 1994; 120(5):279-85. PubMed ID: 7907334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of anti-tumor CD4+ T cell responsiveness in the tumor-bearing state and its recovery in in vitro culture free of tumor burden.
    Nagata T; Zou JP; Yamamoto N; Ono S; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1993 Nov; 84(11):1181-9. PubMed ID: 7903964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-bearing mice exhibit a progressive increase in tumor antigen-presenting cell function and a reciprocal decrease in tumor antigen-responsive CD4+ T cell activity.
    Zou JP; Shimizu J; Ikegame K; Yamamoto N; Ono S; Fujiwara H; Hamaoka T
    J Immunol; 1992 Jan; 148(2):648-55. PubMed ID: 1345922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming growth factor-beta (TGF-beta)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-beta and a progressive increase in TGF-beta susceptibility of anti-tumor CD4+ T cell function.
    Li XF; Takiuchi H; Zou JP; Katagiri T; Yamamoto N; Nagata T; Ono S; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1993 Mar; 84(3):315-25. PubMed ID: 8098027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for the functional binding in vivo of tumor rejection antigens to antigen-presenting cells in tumor-bearing hosts.
    Shimizu J; Zou JP; Ikegame K; Katagiri T; Fujiwara H; Hamaoka T
    J Immunol; 1991 Mar; 146(5):1708-14. PubMed ID: 1993850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
    Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T
    Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12.
    Ogawa M; Tsutsui T; Zou JP; Mu J; Wijesuriya R; Yu WG; Herrmann S; Kubo T; Fujiwara H; Hamaoka T
    Cancer Res; 1997 Jun; 57(11):2216-22. PubMed ID: 9187124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen-presenting cells constitutively bind tumor antigens in the tumor-bearing state in vivo to construct an effective immunogenic unit.
    Shimizu J; Zou JP; Ikegame K; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1991 Mar; 82(3):262-5. PubMed ID: 1902448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential IL-12 responsiveness of T cells but not of NK cells from tumor-bearing mice in IL-12-responsive versus -unresponsive tumor models.
    Iwasaki M; Yu WG; Uekusa Y; Nakajima C; Yang YF; Gao P; Wijesuriya R; Fujiwara H; Hamaoka T
    Int Immunol; 2000 May; 12(5):701-9. PubMed ID: 10784616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells.
    Hamaoka T; Shimizu J; Suda T; Fujiwara H
    Princess Takamatsu Symp; 1988; 19():265-75. PubMed ID: 3269360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells.
    Zou JP; Yamamoto N; Fujii T; Takenaka H; Kobayashi M; Herrmann SH; Wolf SF; Fujiwara H; Hamaoka T
    Int Immunol; 1995 Jul; 7(7):1135-45. PubMed ID: 8527411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of tumor-infiltrating CD4+ T cells as Th1 cells based on lymphokine secretion and functional properties.
    Nagarkatti M; Clary SR; Nagarkatti PS
    J Immunol; 1990 Jun; 144(12):4898-905. PubMed ID: 1972170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells.
    Shimizu J; Suda T; Yoshioka T; Kosugi A; Fujiwara H; Hamaoka T
    J Immunol; 1989 Feb; 142(3):1053-9. PubMed ID: 2464022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of IL-12 induces a CD3+ CD4- CD8- B220+ lymphoid population capable of eliciting cytolysis against Fas-positive tumor cells.
    Tsutsui T; Mu J; Ogawa M; Yu WG; Suda T; Nagaga S; Saji F; Murata Y; Fujiwara H; Hamaoka T
    J Immunol; 1997 Sep; 159(6):2599-605. PubMed ID: 9300678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B cell-mediated down-regulation of IFN-gamma and IL-12 production induced during anti-tumor immune responses in the tumor-bearing state.
    Wijesuriya R; Maruo S; Zou JP; Ogawa M; Umehara K; Yamashita M; Ono S; Fujiwara H; Hamaoka T
    Int Immunol; 1998 Aug; 10(8):1057-65. PubMed ID: 9723691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T cells or macrophages in the tumor-bearing state.
    Yamamoto N; Zou JP; Li XF; Takenaka H; Noda S; Fujii T; Ono S; Kobayashi Y; Mukaida N; Matsushima K
    J Immunol; 1995 Mar; 154(5):2281-90. PubMed ID: 7868900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of interleukin-7, interleukin-2, and interferon-gamma to propagate CD4+ T cells in culture with maintained antigen specificity.
    Cohen PA; Kim H; Fowler DH; Gress RE; Jakobsen MK; Alexander RB; Mulé JJ; Carter C; Rosenberg SA
    J Immunother Emphasis Tumor Immunol; 1993 Oct; 14(3):242-52. PubMed ID: 7507711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid suppressor cell-associated immune dysfunction in CSA1M fibrosarcoma tumor-bearing mice.
    Zhou R; He PL; Ren YX; Wang WH; Zhou RY; Wan H; Ono S; Fujiwara H; Zuo JP
    Cancer Sci; 2007 Jun; 98(6):882-9. PubMed ID: 17433038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor vaccination that enhances antitumor T-cell responses does not inhibit the growth of established tumors even in combination with interleukin-12 treatment: the importance of inducing intratumoral T-cell migration.
    Gao P; Uekusa Y; Nakajima C; Iwasaki M; Nakahira M; Yang YF; Ono S; Tsujimura T; Fujiwara H; Hamaoka T
    J Immunother; 2000; 23(6):643-53. PubMed ID: 11186152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
    Li T; Harada M; Tamada K; Abe K; Nomoto K
    Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.